期刊文献+

VAD方案和PCD方案治疗多发性骨髓瘤的效果临床观察 被引量:4

Clinical observation of VAD regimen and PCD regimen in the treatment of multiple myeloma
下载PDF
导出
摘要 目的分析讨论VAD(表阿霉素+长春新碱+地塞米松)方案和PCD(硼替佐米+环磷酰胺+地塞米松)方案治疗多发性骨髓瘤的临床疗效。方法选取本院2013年1月~2017年12月进行治疗的40例多发性骨髓瘤患者,按照其就诊顺序随机分为常规组和治疗组,每组20例患者,常规组采用VAD方案治疗,治疗组采用PCD方案治疗,经过治疗后,比较分析两组患者的治疗效果、毒性反应发生率以及临床指标。结果在治疗后,治疗组患者的治疗总有效率高于常规组,毒性反应发生率低于常规组,临床指标优于常规组,差异具有统计学意义(P<0.05)。结论 PCD方案治疗多发性骨髓瘤的效果优于VAD方案治疗,能够提高治疗效果,有效改善患者临床指标,有很高的临床应用价值。
出处 《当代医学》 2018年第33期143-145,共3页 Contemporary Medicine
  • 相关文献

参考文献8

二级参考文献61

  • 1邹徳慧.Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma[J].China Medical Abstracts(Internal Medicine),2013,30(2):115-116. 被引量:1
  • 2惠双,王博,王媛,等.沙利度胺联合VAD治疗老年多发性骨髓瘤患者的临床疗效及不良反应探讨.中国生化药物杂志,2014,35(2):90-91,94.
  • 3Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma, ver- sion 1,2013 [ J ]. J N atl Compr Canc Netw,2013,11 ( 1 ) : 11 - 17.
  • 4Tone H,Kurebe M,Takeuchi T,et al. Experimental studies on (2" R) - 4 - 0 - Tetrahydropyranyla driamycin (THP). In kuemmerle HP ed. Advance in experimental and clinical chemotherapy [ C ]. 15th International Congress of Chemotherapy Workshop on Pirarn- bicin, July 19 - 24,1987.
  • 5Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later [ J ]. Blood, 2012,120 ( 5 ) : 947 - 959.
  • 6Richardson P, Chanan - Khan A, Schlossman R,et al. Phase 1I tri- M of single agent bortezomib in patients with previously untreated multiple myeloma(MM) [J]. Blood,2004,104(ll ) :336.
  • 7Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexametha- sone as induction treatment prior to autologous stem cell transplan- tation (ASCT) in patients with newly diagnosed multiple myeloma: Preliminary results of an IFM phase I1 study [ J ]. Hematological, 2006,91 ( 11 ) : 1498 - 1505.
  • 8Dytfeld D, Griffith KA, Friedman J, et al. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortczomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by afree light chain - and M - protein - based model : Extended follow - up of a phase II trial[ J]. Leuk Lymphoma,2011,52( 7 ) : 1271 - 1280.
  • 9Blad6 J, Sonneveld P, San Miguel JF, et al. Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for muhiple myeIoma:Effects of adverse prognostic factors on outcome [ J]. Clin Lymphoma Myeloma Leuk ,2011,11 ( 1 ) :44 - 49.
  • 10Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of re- lapsed and/or refractory muhiple myeloma [ J ]. Ther Clin Risk Manag,2009,5 ( 1 ) : 151 - 159.

共引文献81

同被引文献40

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部